Short Interest Change: Dipexium Pharmaceuticals Incorporated (NASDAQ:DPRX) Can’t Be Less Risky. Short Interest Decreased

December 1, 2016 - By Marie Mckinney   ·   0 Comments

Short Interest Change: Dipexium Pharmaceuticals Incorporated (NASDAQ:DPRX) Can't Be Less Risky. Short Interest Decreased

The stock of Dipexium Pharmaceuticals Incorporated (NASDAQ:DPRX) registered a decrease of 42.29% in short interest. DPRX’s total short interest was 381,100 shares in December as published by FINRA. Its down 42.29% from 660,400 shares, reported previously. With 3.24M shares average volume, it will take short sellers 0 days to cover their DPRX’s short positions. The short interest to Dipexium Pharmaceuticals Incorporated’s float is 7%. The stock last traded at $1.4 per share. It is down 88.76% since April 28, 2016 and is downtrending. It has underperformed by 94.68% the S&P500.

Dipexium Pharmaceuticals, Inc. is a late-stage pharmaceutical company. The company has a market cap of $14.06 million. The Firm is focused on the development and commercialization of Locilex , a first-in-class, broad spectrum, topical antibiotic. It currently has negative earnings. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI).

Insitutional Activity: The institutional sentiment increased to 1.54 in Q2 2016. Its up 0.54, from 1 in 2016Q1. The ratio increased, as 5 funds sold all Dipexium Pharmaceuticals Inc shares owned while 10 reduced positions. 4 funds bought stakes while 11 increased positions. They now own 2.31 million shares or 15.44% less from 2.73 million shares in 2016Q1.
Moreover, Deutsche Commercial Bank Ag has 0% invested in Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) for 1,552 shares. Moreover, Guggenheim Cap Ltd Limited Liability Company has 0% invested in Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) for 37,939 shares. Blackrock Invest Mngmt has 956 shares for 0% of their US portfolio. Wells Fargo & Mn accumulated 0% or 3,300 shares. Geode Mgmt Ltd Liability Com holds 0% of its portfolio in Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) for 33,170 shares. Falcon Point Capital Ltd Company reported 38,833 shares or 0.07% of all its holdings. Raymond James Assoc last reported 31,433 shares in the company. Us Bank & Trust De accumulated 0% or 4,045 shares. Tourbillon Capital Ptnrs Lp holds 0.05% of its portfolio in Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) for 237,874 shares. First New York Securities Limited Liability Ny owns 2,300 shares or 0% of their US portfolio. Blackrock Fund Advisors owns 15,674 shares or 0% of their US portfolio. Morgan Stanley, a New York-based fund reported 5,341 shares. Goldman Sachs Gru Incorporated has invested 0% of its portfolio in Dipexium Pharmaceuticals Inc (NASDAQ:DPRX). Manufacturers Life The holds 0% of its portfolio in Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) for 582 shares. 1492 Cap Mngmt Lc last reported 0.27% of its portfolio in the stock.

Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) Ratings Coverage

Out of 2 analysts covering Dipexium Pharmaceuticals (NASDAQ:DPRX), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Dipexium Pharmaceuticals has been the topic of 3 analyst reports since October 14, 2015 according to StockzIntelligence Inc. The firm has “Mkt Perform” rating given on Wednesday, October 26 by Raymond James. The firm has “Hold” rating by Feltl & Co given on Tuesday, October 25. The firm has “Buy” rating by Raymond James given on Wednesday, October 14.

DPRX Company Profile

Dipexium Pharmaceuticals, Inc., incorporated on January 14, 2010, is a late-stage pharmaceutical company. The Firm is focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a first-in-class, broad spectrum, topical antibiotic. Locilex kills microbial targets by disrupting the bacterial cell membrane. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI). As a topical antibiotic, Locilex affects only the area to which it is applied, and does not spread to the entire body through the bloodstream, which is host to a number of different bacteria other than bacteria causing the skin infection.

More notable recent Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on March 16, 2014, also Prnewswire.com with their article: “Dipexium Pharmaceuticals Reports Third Quarter 2016 Financial Results” published on November 10, 2016, Streetinsider.com published: “Dipexium Pharma (DPRX) Announces Locilex Phase 3s Missed Primary Endpoints” on October 25, 2016. More interesting news about Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) were released by: Prnewswire.com and their article: “Dipexium Pharmaceuticals Reports Second Quarter 2016 Financial Results” published on August 04, 2016 as well as Quotes.Wsj.com‘s news article titled: “News Dipexium Pharmaceuticals Inc.DPRX” with publication date: March 09, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marie Mckinney

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>